Activation of c-Jun N-terminal kinase (JNK) by widely used specific p38 MAPK inhibitors SB202190 and SB203580: a MLK-3-MKK7-dependent mechanism.
about
Molecular mechanisms of liver injury and hepatocarcinogenesis: focusing on the role of stress-activated MAPKLeptin signaling and apoptotic effects in human prostate cancer cell lines.TLR and TNF-R1 activation of the MKK3/MKK6-p38α axis in macrophages is mediated by TPL-2 kinase.Advanced application of bovine intestinal epithelial cell line for evaluating regulatory effect of lactobacilli against heat-killed enterotoxigenic Escherichia coli-mediated inflammation.The new small-molecule mixed-lineage kinase 3 inhibitor URMC-099 is neuroprotective and anti-inflammatory in models of human immunodeficiency virus-associated neurocognitive disorders.Overexpression of C-terminal fragment of glutamate receptor 6 prevents neuronal injury in kainate-induced seizure via disassembly of GluR6-PSD-95-MLK3 signaling module.Fibroblast growth factor 9 activates akt and MAPK pathways to stimulate steroidogenesis in mouse leydig cellsMechanisms of regulation of oligodendrocyte development by p38 mitogen-activated protein kinasep38 mitogen-activated protein kinase-induced nuclear factor kappa-light-chain-enhancer of activated B cell activity is required for neuroprotection in retinal ischemia/reperfusion injurySB203580 increases G-CSF production via a stem-loop destabilizing element in the 3' untranslated region in macrophages independently of its effect on p38 MAPK activity.tPA contributes to impaired NMDA cerebrovasodilation after traumatic brain injury through activation of JNK MAPK.Population PK-PD Model for Tolerance Evaluation to the p38 MAP Kinase Inhibitor BCT197.Inhibition of c-Jun NH2-terminal kinase stimulates mu opioid receptor expression via p38 MAPK-mediated nuclear NF-κB activation in neuronal and non-neuronal cells.MAP3K11/GDF15 axis is a critical driver of cancer cachexiap38(MAPK): stress responses from molecular mechanisms to therapeutics.The p38 MAPK inhibitors for the treatment of inflammatory diseases and cancer.The p38 MAPK Pathway in Rheumatoid Arthritis: A Sideways Look.Regulation of toll-like receptors-mediated inflammation by immunobiotics in bovine intestinal epitheliocytes: role of signaling pathways and negative regulatorsActivation of stress-related signalling pathway in human cells upon SiO2 nanoparticles exposure as an early indicator of cytotoxicity.Differential effects of p38 MAP kinase inhibitors SB203580 and SB202190 on growth and migration of human MDA-MB-231 cancer cell line.Fn14 promotes differentiation of human mesenchymal stem cells into heart valvular interstitial cells by phenotypic characterization.Differential roles of ASK1 and TAK1 in Helicobacter pylori-induced cellular responses.Saturated hydrogen saline ameliorates lipopolysaccharide-induced acute lung injury by reducing excessive autophagy.Activation of the p38 Map kinase pathway is essential for the antileukemic effects of dasatinib.Amelioration of an undesired action of deguelin.Differential effect of p38 and MK2 kinase inhibitors on the inflammatory and toxicity biomarkers in vitro.High-yield of biologically active recombinant human fibroblast growth factor-16 in E. coli and its mechanism of proliferation in NCL-H460 cells.Decreased SAPK/JNK signalling affects cytokine release and STAT3 activation in psoriatic fibroblasts.
P2860
Q28384866-32819F7C-9106-4BAC-9349-0F5E3B68B299Q33889654-D1A37265-E5F1-4EBD-BF1D-383B247D4149Q34533855-05850F57-1EA0-49B1-A6B0-83D9EB81E517Q34622432-511CDB5F-3C82-41C1-85EB-6BB86904AB7FQ34769218-7104B832-FFBF-4C43-8614-CBDAC7AD4C4DQ35047000-B8FC9E68-FE23-4EA4-A837-DF6A03DC711EQ35113258-BB3BEB8D-8C9D-44FD-A9C7-4BB51114F211Q35892864-4A0B73C5-23B0-4F56-BBB8-D85EBD8762D9Q36145965-59337FB5-5CBC-4027-A999-6DC6A60111DFQ36469025-5E40A821-6493-414E-ADEE-53BBC6B277E7Q36469555-DFF87E05-3671-4A0E-B6D5-9FB007401043Q36595924-5677A04D-6B12-4F2B-9830-5E9CDB6EEA48Q36771850-CD3FE26E-32EE-4681-BCE4-DD04E47F2CC6Q36892019-C34561F1-592E-4E57-8C9B-B3771A644D15Q37576462-348D9F8D-9F79-4F4C-9E51-014970443A4BQ37620350-E7EA4D39-B95E-4432-932F-8868A8BA5C9FQ38048776-BB42D146-2345-4BEA-8186-0C98AB0A7771Q38250324-FE40A611-9C3C-4853-B26B-B06DC2328869Q38275446-D3F5C7EA-B9AD-414A-BB68-D5EC427FAD8CQ38708289-0D8F7AD7-C63C-4E68-B29D-3AAC0CB055D9Q39079717-15306A74-A749-45AF-9F69-0AF4AD53D659Q39089445-95C1FFBE-93E5-446D-A45A-8D83846661C2Q39360966-102BEE95-4E24-4AC8-8BDC-6AFB0AE67A3EQ39813618-6E87C548-94EC-4CC0-909B-CB4218F766D2Q42957683-5767CCED-C904-4B04-8BAA-514C6205672CQ48752249-17338A4F-5C9B-487C-8895-80F6425F61EDQ50443999-5D1A9C36-E05A-4CCC-8B5C-5AB9332B7240Q53449858-8BAE7742-6801-4291-A973-7FEFF0E55887
P2860
Activation of c-Jun N-terminal kinase (JNK) by widely used specific p38 MAPK inhibitors SB202190 and SB203580: a MLK-3-MKK7-dependent mechanism.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Activation of c-Jun N-terminal ...... LK-3-MKK7-dependent mechanism.
@en
Activation of c-Jun N-terminal kinase
@nl
type
label
Activation of c-Jun N-terminal ...... LK-3-MKK7-dependent mechanism.
@en
Activation of c-Jun N-terminal kinase
@nl
prefLabel
Activation of c-Jun N-terminal ...... LK-3-MKK7-dependent mechanism.
@en
Activation of c-Jun N-terminal kinase
@nl
P2860
P1433
P1476
Activation of c-Jun N-terminal ...... LK-3-MKK7-dependent mechanism.
@en
P2093
Harish Muniyappa
Kumuda C Das
P2860
P304
P356
10.1016/J.CELLSIG.2007.12.003
P577
2007-12-08T00:00:00Z